---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022759"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:46:25.177496+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M

## Summary
- Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.
- Adjusted EBITDA $(47)M improved from $(117)M; cash & equivalents $517M.
- Raises FY2025 total revenue guidance to $167-187M (from $160-180M); Cell Eng. guidance $117-137M.
- Cost reduction target: $250M annualized by Q3 2025; achieved $205M run-rate in Q1.
- Awarded $29M ARPA-H contract for distributed manufacturing using wheat germ cell-free systems.

## SEC filing metadata
- accession: 0001628280-25-022759
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/0001628280-25-022759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/dna-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022759
- JSON: https://secwatch.observer/filing/0001628280-25-022759.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.